Gene-Editing Startup Raises $230M for Rare Disease Cure

A new biotech company just launched with $230 million to develop a one-time cure for a genetic disease affecting thousands.

Serapha Bio aims to fix the root cause of Alpha-1 Antitrypsin Deficiency using cutting-edge gene editing.